• damage to relationships with any potential collaborators; • injunctions or the imposition of civil or criminal penalties; or 71 Table of Contents Table of Contents Table of Contents Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving ...

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O'Connor, M.D., as chief medical of icer and Pasit Phiasivongsa, Ph.D., as chief technical of icer Strengthened financial position ending the quarter with cash and mar ...

Contacts: Investors Jason Kantor, Ph.D. Nurix Therapeutics, Inc. ir@nurixtx.com Elizabeth Wolffe, Ph.D. Wheelhouse Life Science Advisors lwolffe@wheelhouselsa.com Media Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com Nurix Therapeutics, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited) Nurix Therapeutics, Inc. Condensed Consolidated Balance Sheets (in thousands) (unaudited) | --- | --- | --- | --- | --- | --- | - ...

SAN FRANCISCO, July 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the second quarter ended May 31, 2024, and provided a corporate update. Strengthened leadership with appointment of Paula G. O'Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer "Our se ...

SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the UBS Virtual Targeted Protein Degradation (TPD) Day, at 2:30 p.m. ET on Monday, July 15, 2024. Media The event will be webcast l ...

Nurix Therapeutics, Inc. (NRIX) shares rallied 20.6% in the last trading session to close at $18.44. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.6% loss over the past four weeks. This company is expected to post quarterly loss of $0.70 per share in its upcoming report, which represents a year-over-year change of -55.6%. Revenues are expected to be $19.35 million, down 36.9% from the year-ago quarter. Fo ...

Media Aljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 "The current results from this study of advanced patients are very impressive for this early stage of development and we are optimistic that NX-5948 has the potential to be an exciting breakthrough for patients with relapse ...

Details of the webcast and conference call are as follows: Details of the oral presentation at EHA2024 are as follows: NX-5948 is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Nurix has previously reported that NX-5948 is highly potent against a range of tumor cell lines that are resistant to current BTK inhibitor therapies, an important co ...

Dr. Lacey, who has served on the Nurix board since 2016, and as board chair since 2019, will remain on the board and will continue to serve as chair of its Compensation Committee and as a member of its Development Advisory Committee. "Nurix is extremely fortunate to have benefited from David's exceptional guidance as chair over the last five years. His scientific and medical insight has been instrumental in our growth from a private, ligase research company to a public, drug discovery and development compan ...

David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L. Lacey, M.D., steppe ...